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Abstract
Background: Many patients with asthma require frequent rescue medication for acute symptoms despite
appropriate controller therapies. Thus, determining the most effective relief regimen is important in the
management of more severe asthma. This study’s objective was to evaluate whether ipratropium bromide/albuterol
metered-dose inhaler (CVT-MDI) provides more effective acute relief of bronchospasm in moderate-to-severe
asthma than albuterol hydrofluoroalkaline (ALB-HFA) alone after 4 weeks.
Methods: In this double-blind, crossover study, patients who had been diagnosed with asthma for ≥1 year were
randomized to two sequences of study medication “as needed” for symptom relief (1–7 day washout before
second 4-week treatment period): CVT-MDI/ALB-HFA or ALB-HFA/CVT-MDI. On days 1 and 29 of each sequence,
6-hour serial spirometry was performed after administration of the study drug. Co-primary endpoints were FEV1
area under the curve (AUC0–6) and peak (post-dose) forced expiratory volume in 1 s (FEV1) response (change
from test day baseline) after 4 weeks. The effects of “as needed” treatment with ALB-HFA/CVT-MDI were analyzed
using mixed effect model repeated measures (MMRM).
Results: A total of 226 patients, ≥18 years old, with inadequately controlled, moderate-to-severe asthma were
randomized. The study met both co-primary endpoints demonstrating a statistically significant treatment benefit
of CVT-MDI versus ALB-HFA. FEV1 AUC0-6h response was 167 ml for ALB-HFA, 252 ml for CVT-MDI (p <0.0001);
peak FEV1 response was 357 ml for ALB-HFA, 434 ml for CVT-MDI (p <0.0001). Adverse events were comparable
across groups.
Conclusions: CVT-MDI significantly improved acute bronchodilation over ALB-HFA alone after 4 weeks of
“as-needed” use for symptom relief, with a similar safety profile. This suggests additive bronchodilator effects
of β2-agonist and anticholinergic treatment in moderate-to-severe, symptomatic asthma.
Trial registration: ClinicalTrials.gov No.: NCT00818454; Registered November 16, 2009.
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Background
Despite the availability of effective asthma controller
therapies, a significant proportion of patients have sub-
optimal asthma control, characterized by frequent symp-
toms, lifestyle restrictions, and healthcare use [1–3]. In
addition to controller medications, acute reliever or res-
cue medications, e.g. short-acting β2-agonists (SABAs)
are used to treat acute symptoms and exacerbations [4].
The frequency of SABA use as rescue medication reflects
the frequency and intensity of symptoms, and is an im-
portant component for classifying asthma severity and
level of disease control [4–6].
Short-acting anticholinergic agents have been used in
asthma for decades; however, their exact role in asthma
has not been well established [7, 8]. Studies directly
comparing short-acting anticholinergic agents with a
variety of SABAs have shown that SABAs provide
greater bronchodilation than short-acting anticholinergic
agents alone in stable asthma [9–11]; however, individual
studies have demonstrated that specific asthma popula-
tions, e.g. older patients [12], and those whose asthma is
related to psychogenic factors [13, 14], cigarette smoke,
or β-blocking drugs [15, 16], might benefit from anti-
cholinergic therapy.
Short-acting anticholinergic agents have also been
evaluated in combination with a SABA or sequentially
following SABA administration. The rationale for use
of a combination of a short-acting anticholinergic agent
and a SABA includes differences between the two clas-
ses of medications regarding mechanisms of action,
side-effect profiles, onset and duration of action, and
site of action [9]. Studies evaluating combination therapy
with a short-acting anticholinergic and a SABA have
shown variable results, mainly due to small numbers of
patients or inappropriate patient populations [8, 11, 17–
24]; however, many of these studies showed an additional
(although not significant) benefit [8].
Combivent® inhalation aerosol metered-dose inhaler
(CVT-MDI) is a fixed-dose combination of the short-
acting anticholinergic, ipratropium bromide, and the SABA,
albuterol sulfate, using a chlorofluorocarbon (CFC) propel-
lant. It should be noted that the CFC-MDI formulation of
Combivent (CVT-MDI) used in this study is no longer
available, but Combivent is available in the Respimat® Soft
Mist™ inhaler (Combivent® Respimat®), which is considered
therapeutically equivalent to the CFC-MDI formulation,
and studies in chronic obstructive pulmonary disease
(COPD) have indicated that it has similar bronchodilator
effects [25, 26].
A prior, single-dose, double-blind, crossover study
compared CVT-MDI to albuterol hydrofluoroalkaline
(ALB-HFA) in patients with moderate-to-severe asthma
and persistent symptoms. These patients required regu-
lar use of albuterol as rescue medication (6–56 puffs per
week) despite medium- to high-dose inhaled corticosteroids
(ICS), with or without long-acting β2-agonist (LABA) [22].
Patients demonstrated significant improvement in pulmon-
ary function after treatment with CVT-MDI versus ALB-
HFA alone. We designed a study based on these results,
and according to results from the Asthma Clinical Research
Network studies [27], which indicated that inhaled long-
acting muscarinic antagonists (LAMAs) might be an alter-
native to LABAs and other controllers in patients whose
condition is inadequately controlled on an ICS alone [28].
The objective of this study was to evaluate whether
CVT-MDI provides more effective acute relief of broncho-
spasm in moderate-to-severe asthma than ALB-HFA
alone after 4 weeks, as add-on to stable doses of their con-
troller medications (ICS, LABA, leukotriene modifier,
theophylline, anti IgE, oral corticosteroids). Patients were
required to be on stable doses of these medications for at
least 4 weeks prior to screening to achieve a clear baseline
before study commencement. The efficacy of CVT-MDI
or ALB-HFA was compared for acute improvement in
lung function at the beginning and end of treatment, and
other measures of asthma control (medication was with-
held before measurement of acute response). Patients
were instructed to use open-label ALB-HFA in addition to
the blinded study medication if required.
Methods
Ethics, consent and permissions
This randomized, double-blind, two-way crossover study
was conducted in accordance with the Declaration of
Helsinki. The protocol and all amendments were approved
by the institutional review board/ethics committee at each
participating site (Additional file 1: Table S1). All patients
provided written informed consent.
Trial design
Every effort was made to collect spirometry data for
each time-point at the clinic visit. To be able to include
the same patients at each time-point in the spirometry
summaries, missing values were estimated using other
values recorded for the patient on that test day. For patients
with missing data on a given test-day because additional
SABA medication was taken during testing, missing data
were estimated by the least favorable observation on that
test-day. Randomly missing data were estimated by either
linear interpolation of adjacent data or by the last observed
data if no subsequent data were available. The decision to
use estimates for missing data was made prior to unblind-
ing of the treatment assignments.
Participants
Patients were male or female, ≥18 years of age, with
physician diagnosis of asthma for ≥1 year, baseline forced
expiratory volume (FEV1) ≤80 % predicted normal and
Donohue et al. BMC Pulmonary Medicine  (2016) 16:65 Page 2 of 15
post-bronchodilator reversibility of ≥12 % or ≥200 ml after
administration of four puffs of ALB-HFA. Spirometry was
performed according to American Thoracic Society guide-
lines [29, 30], and National Health and Nutrition Examin-
ation Survey reference equations were used to calculate
predicted values [31]. Patients received treatment with
ICS with or without LABA and other asthma controller
medications for ≥6 weeks prior to screening, and used a
short-acting bronchodilator ≥3 times a week for symptom
relief in the 2 weeks prior to screening. Patients were en-
tered in the study only if they had an Asthma Control
Questionnaire (ACQ) score of ≥1.5 [32].
Patients were excluded from the study if they had been
diagnosed with COPD or other significant disease; how-
ever, all patients who were non-smokers or ex-smokers
who stopped smoking for >1 year prior to study partici-
pation and had a smoking history <10 pack-years were
eligible. Patients who had been hospitalized for cardiac
failure in the past year or who had a recent history of
myocardial infarction were excluded.
The study included a 2-week screening period to es-
tablish patients’ baseline asthma measures and confirm
eligibility using bronchodilator reversibility testing—12 %
and 200 ml improvement in FEV1 post-bronchodilator
after four puffs of ALB-HFA MDI—at visit two. Patients
recorded symptoms, medication use (maintenance ICS ±
LABA and “as needed”) and peak expiratory flow (PEF)
in an electronic diary (eDiary)/peak flow meter (Asthma
Monitor® [AM3]; ERT Products, Philadelphia) during the
screening period. After the run-in period, eligible pa-
tients were randomly assigned (1:1) to either CVT-MDI
or ALB-HFA. Patients used blinded study medication as
needed (two puffs every 4–6 h, up to four times daily)
between visits for symptom relief during the 4-week
treatment period. Additionally, patients received open-
label ALB-HFA for use if symptom relief could not be
achieved with the blinded study medication. Mainten-
ance therapy with high- or low-dose ICS had no impact
on outcomes (Table 2) and, as this was a crossover
study, all patients served as their own control.
Following the first 4-week treatment period, patients
had a 1–7 day washout period (a 6–8-hour wash-out
period is generally considered adequate for short-acting
antimuscarinics (SAMAs) before entering the second 4-
week treatment period with crossover treatment using
either CVT-MDI or ALB-HFA. All other (non-asthma)
concomitant therapies taken at screening and through-
out the trial period were recorded. For washout, patients
were instructed to refrain from using their study medica-
tion for at least 6 h prior to the scheduled clinic visit.
On days 1 and 29, patients underwent lung function
testing with 6-hour serial spirometry. Baseline FEV1 was
measured 10-minutes before, and at 5, 15, 30, 60 min,
and 2, 3, 4, 5, 6 h after study drug administration.
Patients were instructed to use the asthma monitor
(AM3) throughout the study. Patients used the AM3 to
record twice-daily peak expiratory flow (PEFs), as-needed
study medication use, additional open-label ALB-HFA
use, daily symptom assessments, and background con-
troller medication use (such as ICS, LABA, leukotriene
modifier, theophylline, anti IgE, OCS) for the duration
of the study.
Interventions
CVT-MDI (Combivent® Inhalation Aerosol CFC-MDI
(Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield
CT, USA) or ALB-HFA (IVAX Pharmaceuticals, Water-
ford, Ireland) was used during clinic visit days for pul-
monary function testing, and as needed between clinic
visits for symptom relief. Each actuation of CVT-MDI
delivered 18 μg ipratropium bromide and 103 μg albute-
rol sulfate (equivalent to 90 μg albuterol base) from the
mouthpiece. For the ALB-HFA MDI, each actuation de-
livered 120 μg albuterol sulfate from the canister valve
and 108 μg albuterol sulfate from the actuator mouth-
piece (equivalent to 90 μg albuterol base). During each
treatment period, patients recorded in their eDiary the
number of puffs of study medication taken (AM and PM).
If patients perceived that study medication was not
adequately controlling their asthma symptoms, they were
instructed to use the open-label ALB-HFA (ProAir® HFA,
IVAX Pharmaceuticals, Waterford, Ireland) in addition to
the study medication.
For the study duration, patients were required to re-
main on stable doses of their asthma controller medica-
tions and changes in background controller medications
were documented. Additions or increases in the dose of
oral corticosteroids were allowed for the management of
asthma exacerbations and were recorded.
Study end points
Co-primary endpoints were FEV1 area-under-the-curve
(AUC0–6) above test-day baseline from 0 to 6 h, and
peak FEV1 response. The study defined peak FEV1 re-
sponse as the maximum change in FEV1 from test-day
baseline within the 6-hour post-treatment interval, after
4 weeks of treatment.
The secondary endpoints were the mini Asthma Quality
of Life Questionnaire (mini-AQLQ) responses, ACQ-7 re-
sponses, and the number of puffs of study medication and
open-label ALB-HFA (AM and PM) patients used during
each treatment period. Other endpoints included forced
vital capacity, peak expiratory flow (data not shown), night-
time awakenings due to asthma symptoms (from eDiary),
and duration of bronchodilator FEV1 response. Broncho-
dilator response was achieved if an FEV1 value of ≥1.15
times the corresponding test-day baseline value was re-
corded at any time-point during the first 6 h after treatment
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administration. Termination of bronchodilator response
was identified by the first fall of <1.15 times the corre-
sponding test-day FEV1 baseline value on two consecutive
measurements following a bronchodilator response during
the 6-hour observation period on the test day. Duration of
bronchodilator response was defined as the time interval
between onset (bronchodilator response first achieved) and
termination of bronchodilator response; duration was zero
if there was no bronchodilator response.
Safety endpoints included monitoring of adverse events
(AEs), vital signs, screening laboratory values (hematology,
chemistry, and urinalysis), and electrocardiogram (ECG).
Statistical methods
Co-primary efficacy endpoints of CVT-MDI and ALB-
HFA were compared using mixed-effect model repeated
measures (MMRM). The MMRM model has treatment,
period, day, and the interaction between treatment and
day as fixed effects, test-day baseline value as a covariate,
and patient as random effect. In the MMRM model, day
refers to the start (day 1) or end (day 29) of 4 weeks of
treatment. In the results section, only results for day 29
will be presented. A hierarchical testing procedure was
used to address multiple comparisons. The null hypothesis
for FEV1 AUC0–6 response was tested first (alpha = 0.025,
CONSORT Flow Diagram
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Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flowchart of patient disposition
Donohue et al. BMC Pulmonary Medicine  (2016) 16:65 Page 4 of 15
one-sided); if this null hypothesis was rejected, the null
hypothesis for peak FEV1 response was tested next
(alpha = 0.025, one-sided).
The primary efficacy analysis was performed on a
modified full analysis set (FAS). The FAS consisted of
all patients receiving study medication, who were docu-
mented to have taken at least one dose of investigational
drug, and who had no missing test-day baseline values or
missing responses for FEV1 AUC0–6 and peak FEV1 after
4 weeks of treatment. Seven patients who reported that
their study medication devices were working improperly,
and whose treatment blind was broken prior to database
lock, were excluded from all efficacy analyses.
A post-hoc analysis was also performed on endpoints
related to the co-primary endpoints. The MMRM model
described above was used to analyze the ratio of FEV1
AUC0–6 response to test-day baseline FEV1, and the ratio
of peak FEV1 response to test-day baseline FEV1.
Subgroup analyses for the co-primary endpoints were
performed for: onset of asthma; type of asthma; percent
predicted FEV1 categories; concomitant asthma medica-
tion usage; puff usage of medication at study baseline;
gender; race; age categories; smoking status; and FEV1/
forced vital capacity (FVC) percentage categories based
on pre-bronchodilator measurements at randomization.
Subgroup analyses were performed to test whether the
treatment effect was uniform across subgroups, at the end
of the 4-week treatment period.
Secondary endpoints were analyzed using the MMRM
model described for the primary analysis. The analysis of
the duration of bronchodilator response was pre-specified
as descriptive statistics; a post-hoc analysis of bronchodila-
tor response duration on day 29 was also performed using
an MMRM model with treatment and period as fixed
effects, and patient as random effect.
A post-hoc responder analysis (McNemar’s sign test)
was performed to test for the difference in the proportion
of responders (those who achieved bronchodilator FEV1
response) between treatment groups.
All safety data were displayed and analyzed using de-
scriptive statistical methods.
Based on a recent, single-dose, crossover trial with
CVT-MDI and ALB-HFA, the standard deviation for the
difference between treatment groups (paired t-test) in
FEV1 AUC0–6 was expected to be 200–220 ml [22]. For
the peak FEV1 endpoint, the mean difference between
treatments and the standard deviation of the mean treat-
ment difference were expected to be similar to that ob-
served for FEV1 AUC0–6 (usually AUC0–3 is similar to
peak FEV1 – AUC0–6 also includes duration of effect of
these relatively short-acting bronchodilators).
To detect a 60 ml difference in mean values (based on
the single-dose crossover trial) using a 2.5 % level of sig-
nificance (one-tailed) and 90 % power, a sample of
approximately 144 completed patients was calculated;
this was increased to 200 to adjust for patients who
dropped out prior to completing both 4-week periods.
With an estimated 15 % discontinuation rate, 170 pa-
tients were expected to complete the first and second
periods of the crossover (phases I and II).
Results
A total of 548 patients recruited from 41 study centers
in the United States from December 2008 to September
2009 were screened and 226 patients were randomized
using a validated system and received at least one dose
of study medication; 222 randomized patients were treated
with ALB-HFA, and 219 with CVT-MDI (107 received
ALB-HFA, then CVT-MDI and 112 received CVT-MDI,
then ALB-HFA). During the crossover period, 14 patients
prematurely discontinued study medication; three patients
had AEs leading to discontinuation (one taking ALB-HFA,
two taking CVT-MDI), and only 3 % of patients had
Table 1 Summary of demographic and baseline characteristics
of randomized patients
Total No. of randomized patients, no (%) 226 (100)
Female, no. (%) 130 (57.5)
Race, no. (%) White 174 (77)
Black African/Asian 44 (19.5)
Other 8 (3.5)
Age, mean (SD) 47.1 (13.7)
Body mass index (kg/m2), mean (SD) 31.1 (6.7)
Smoking history, no. (%) Never smoked 163 (72.1)
Ex-smoker 63 (27.9)
Characteristics
FEV1 (L), mean (SD) 2.075 (0.630)
% predicted FEV1, mean (SD) 63.4 (11.3)
FEV1/FVC (%), mean (SD) 64.4 (10.3)
FEV1 reversibility (%), mean (SD) 25.7 (15.6)
ACQ score, mean (SD) 2.46 (0.57)
Mini-AQLQ score, mean (SD) 4.52 (1.04)
Open-label albuterol usea, mean (SD) 3.63 (1.62)
Controller: ICS + LABA during the cross-over phase (%) 160 (70.8)
Controller: ICS (low doseb) (%) 52 (23.0)
Controller: ICS (medium doseb) (%) 157 (69.5)
Controller: ICS (high doseb) (%) 17 (7.5)
ACQ asthma control questionnaire (7-point scale), AQLQ asthma quality of life
questionnaire, FEV1 forced expiratory volume in 1 s, ICS inhaled corticosteroid,
LABA long acting β2-agonist
aWeekly mean puffs albuterol/day
bDose either as ICS monotherapy (low-dose ICS, <320 μg: 9/52 patients [17 %];
medium-dose ICS, >320 – <800 μg: 63/157 patients [40 %]; high-dose ICS, >800 μg:
1/17 patients [6 %]), or ICS component of combination ICS/LABA therapy (low-dose
ICS component: 43/52 patients [83 %]; medium-dose ICS component: 94/157
patients [60 %]; high-dose ICS component: 16/17 patients [94 %])
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missing data. Patient disposition is presented in Fig. 1, and
demographics and baseline characteristics in Table 1.
At day 29, mean change in FEV1 AUC0–6 from test-
day baseline was 85 ml greater with CVT-MDI versus
ALB-HFA (252 ml vs. 167 ml, p <0.0001) (Fig. 2a). In a
post-hoc analysis, at day 29, the mean ratio of FEV1
AUC0–6 response to test-day baseline FEV1 was 13 % for
CVT-MDI and 8.3 % for ALB-HFA (p <0.0001) (Fig. 2b).
The mean test-day baseline at day 29 for FEV1 was
219.3 ml for CVT-MDI and 212.6 ml for ALB-HFA.
Mean change from test-day baseline in peak FEV1 for
CVT-MDI was 77 ml greater than ALB-HFA (434 ml vs.
Fig. 2 Change from test-day baseline (SE) in FEV1 AUC0–6 and peak FEV1 after 4 weeks. Mean (adjusted) change and post-hoc analysis of mean
ratio of change from test-day baseline (SE) in FEV1 AUC0–6 and peak FEV1 after 4 weeks using the mixed-effect model repeated measures (MMRM).
a Mean (adjusted) change from test-day baseline in FEV1 AUC 0–6 (ml) (95 % CI of the difference: (0.058, 0.112) p <0.0001); b Mean ratio of
change from test-day baseline in FEV1 AUC0-6 (%) (95 % CI of the difference: (0.032, 0.061) p <0.0001); c Mean (adjusted) change from test-day
baseline in peak FEV1 (ml) (95 % CI of the difference: (0.047, 0.107) p <0.0001); d Mean ratio of change from test-day baseline in peak FEV1 (%)
(95 % CI of the difference: (0.027, 0.060) p <0.0001)
Fig. 3 Changes from test-day baseline in FEV1. Estimated mean (adjusted) changes from test-day baseline in FEV1 at post-dose time-points after
4 weeks using the mixed-effect model repeated measures (MMRM) (day 29; range of difference 50 ml to 115 ml, p <0.006 for all comparisons)
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Table 2 FEV1 AUC0−6 [L] treatment comparisons by subgroups – FAS
Subgroup Subgroup level Number of patients
ALB-HFA 108/CVT-MDI
18/103
Subgroup by
treatment
interaction
Difference (CVT-MDI 18/103 –
ALB-HFA 108)
p value* Mean (SE) 95 % CI P value
Onset of asthma 0.0463
Early 98/98 0.114 (0.024) (0.067, 0.161) <.0001
Late 117/114 0.063 (0.016) (0.031, 0.095) 0.0002
Type of asthma (based on patient history) 0.6444
Allergic 182/181 0.089 (0.015) (0.060, 0.119) <.0001
Non−allergic 33/31 0.079 (0.036) (0.005, 0.154) 0.0364
% Predicted FEV1 categories 0.3127
≤45 % 17/19 0.044 (0.046) (−0.056, 0.144) 0.3562
>45 % and ≤55 % 33/32 0.138 (0.037) (0.062, 0.214) 0.0011
>55 % and ≤65 % 55/54 0.094 (0.030) (0.034, 0.154) 0.0026
>65 % and ≤75 % 76/75 0.073 (0.020) (0.032, 0.113) 0.0006
>75 % 34/32 0.061 (0.033) (−0.005, 0.127) 0.0683
Concomitant asthma medication usage 0.7610
ICS, with LABA 153/149 0.090 (0.018) (0.055, 0.125) <.0001
ICS, without LABA 62/63 0.074 (0.018) (0.037, 0.110) 0.0001
Puff usage of medication (at baseline, daily
average in week prior to visit 3)a
0.9938
≤4 puffs per
24 h day
143/141 0.080 (0.016) (0.048, 0.111) <.0001
>4 and <8 puffs per
24 h
71/70 0.094 (0.027) (0.040, 0.148) 0.0010
≥8 puffs per
24 h day
1/1
Gender 0.2585
Female 125/127 0.2585 0.091 (0.015) (0.060, 0.121) <.0001
Male 90/85 0.082 (0.023) (0.036, 0.128) 0.0007
Raceb 0.1311
Amer.Ind./Alaska Nat 1/1
Asian 2/2
Black/African Amer. 42/40 0.164 (0.041) (0.082, 0.247) 0.0002
Hawaiian/Pacif. Isle 4/5
White 166/164 0.074 (0.014) (0.046, 0.102) <.0001
Age category 0.7044
<35 44/41 0.076 (0.051) (−0.028, 0.180) 0.1464
≥35, <50 68/69 0.082 (0.020) (0.042, 0.123) 0.0001
≥50, <60 62/60 0.115 (0.022) (0.071, 0.159) <.0001
≥60 41/42 0.074 (0.027) (0.019, 0.129) 0.0094
Smoking status 0.9982
Ex-smoker 59/59 0.077 (0.026) (0.026, 0.128) 0.0038
Never smoked 156/153 0.088 (0.016) (0.057, 0.119) <.0001
FEV1/FVC [%] pre−BD at Rand 0.1453
<60 59/60 0.132 (0.027) (0.079, 0.186) <.0001
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357 ml, p <0.0001) (Fig. 2c). In a post-hoc analysis, at
day 29, the mean ratio of peak FEV1 response to test-day
baseline FEV1 was 22 % for CVT-MDI and 17.6 % for
ALB-HFA (p <0.0001) (Fig. 2d). The mean change from
test-day baseline in FEV1 was greater at all post-dose
time-points in those receiving CVT-MDI (Fig. 3).
Greater bronchodilation with CVT-MDI than with
ALB-HFA was noted in all subgroups. The subgroup
analyses demonstrated that treatment differences were
consistent across the subgroups, with no significant
treatment by subgroup interactions (Table 2 and Fig. 4
[FEV1 AUC0–6] and Table 3 and Fig. 5 [peak FEV1]). The
single exception was a marginally significant treatment
by subgroup interaction for the subgroup of onset of
asthma for FEV1 AUC0–6 (p = 0.0463); however, this study
was not powered to assess whether all subjects with more
severe asthma and low lung function (FEV1 <45 % pre-
dicted) would benefit from the regime.
During each 4-week period of active treatment, there
were no significant differences between CVT-MDI and
ALB-HFA in number of puffs of study medication used
or in number of puffs of open-label (rescue) ALB-HFA
used (Table 4). No significant differences were observed
in ACQ or mini-AQLQ questionnaire scores, or in the
number of nighttime awakenings evaluated at the end of
the treatment period (Table 5).
Table 2 FEV1 AUC0−6 [L] treatment comparisons by subgroups – FAS (Continued)
≥60, <65 46/45 0.117 (0.026) (0.063, 0.170) <.0001
≥65, <70 43/44 0.074 (0.029) (0.015, 0.132) 0.0148
≥70 67/63 0.022 (0.024) (−0.025, 0.070) 0.3506
ALB-HFA albuterol hydrofluoroalkaline, CVT-MDI ipratropium bromide/albuterol sulfate metered-dose inhaler, FAS full analysis set, FEV1 forced expiratory volume in
1 s, FVC forced vital capacity, ICS inhaled corticosteroids, LABA long-acting β2-agonist, pre-BD at Rand pre-bronchodilator at randomization
aLast category not included in modelling due to insufficient number of patients
bAsian, Hawaiian/Pacific Islander and American Indian/Alaska National not included in modelling due to insufficient number of patients
*Unadjusted p values
Fig. 4 Forest plot of all subgroups for FEV1 AUC0–6
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Table 3 Peak FEV1 [L] treatment comparisons by subgroups − FAS
Subgroup Subgroup level Number of patients
ALB-HFA 108/CVT-MDI
18/103
Subgroup by
treatment
interaction
Difference (CVT-MDI 18/103 –
ALB-HFA 108)
p value* Mean (SE) 95 % CI P value
Onset of asthma 0.7890
Early 98/98 0.076 (0.024) (0.028, 0.124) 0.0023
Late 117/114 0.078 (0.021) (0.037, 0.118) 0.0003
Type of asthma (based on patient history) 0.3838
Allergic 182/181 0.082 (0.017) (0.049, 0.116) <.0001
Non−allergic 33/31 0.067 (0.035) (−0.005, 0.138) 0.0679
% Predicted FEV1 categories 0.1378
≤45 % 17/19 0.004 (0.046) (−0.094, 0.102) 0.9317
>45 % and≤ 55 % 33/32 0.142 (0.040) (0.060, 0.225) 0.0013
>55 % and≤ 65 % 55/54 0.081 (0.029) (0.022, 0.140) 0.0081
>65 % and≤ 75 % 76/75 0.059 (0.020) (0.018, 0.100) 0.0052
> 75 % 34/32 0.090 (0.053) (−0.016, 0.196) 0.0949
Concomitant asthma medication usage 0.5364
ICS, with LABA 153/149 0.082 (0.018) (0.047, 0.117) <.0001
ICS, without LABA 62/63 0.071 (0.031) (0.009, 0.132) 0.0251
Puff usage of medication (at baseline,
daily average in week prior to visit 3)a
0.8736
≤4 puffs per 24 h day 143/141 0.074 (0.016) (0.042, 0.107) <.0001
>4 and <8 puffs per 24 h 71/70 0.094 (0.035) (0.025, 0.164) 0.0083
≥8 puffs per 24 h day 1/1
Gender 0.1187
Female 125/127 0.090 (0.019) (0.052, 0.127) <.0001
Male 90/85 0.067 (0.024) (0.018, 0.115) 0.0076
Raceb 0.0980
Amer.Ind./Alaska Nat 1/1
Asian 2/2
Black/African Amer. 42/40 0.188 (0.050) (0.089, 0.288) 0.0004
Hawaiian/Pacif. Isle 4/5
White 166/164 0.063 (0.015) (0.034, 0.092) <.0001
Age category 0.7860
<35 44/41 0.077 (0.050) (−0.023, 0.177) 0.1280
≥35,< 50 68/69 0.083 (0.031) (0.022, 0.144) 0.0079
≥50,< 60 62/60 0.097 (0.022) (0.053, 0.142) <.0001
≥ 60 41/42 0.061 (0.030) (0.001, 0.121) 0.0459
Smoking status 0.9106
Ex−smoker 59/59 0.075 (0.037) (0.002, 0.149) 0.0436
Never smoked 156/153 0.076 (0.016) (0.045, 0.107) <.0001
FEV1/FVC [%] pre−BD at Rand 0.1852
<60 59/60 0.145 (0.036) (0.074, 0.217) 0.0001
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In a post-hoc analysis, the duration of bronchodilator
response at the end of the treatment period was twice as
long with CVT-MDI versus ALB-HFA (137.5 min vs.
66.6 min, nominal p <0.0001). In another post-hoc ana-
lysis, the proportion of responders (peak FEV1 response
at 4 weeks that was ≥1.15 times the test−day baseline)
was significantly greater with CVT-MDI than ALB-HFA:
59.2 % versus 45.6 %, nominal p = 0.0014.
Among the 226 patients randomized, 68 (30.1 %) re-
ported at least one AE, with 22.8 % of the CVT-MDI
group (mainly due to the higher frequency of cough with
CVT-MDI) versus 14 % of patients in the ALB-HFA
group reporting an AE. Severe asthma exacerbations
(defined in the protocol as worsening of asthma requiring
treatment with IV or oral corticosteroids) were reported
by seven CVT-MDI patients versus two ALB-HFA pa-
tients (none related to study drug). No severe asthma ex-
acerbations were classified as a serious AE or resulted in
hospitalization, and no fatal events occurred (Table 6).
Discussion
This study found a statistically significantly greater bron-
chodilator effect of CVT-MDI versus ALB-HFA after
4 weeks of “as needed” use of rescue medication, in patients
with moderate-to-severe asthma, confirming results from a
previous single-dose study [22]. CVT-MDI demonstrated
Table 3 Peak FEV1 [L] treatment comparisons by subgroups − FAS (Continued)
≥60,< 65 46/45 0.100 (0.029) (0.041, 0.159) 0.0013
≥65,< 70 43/44 0.056 (0.031) (−0.007, 0.119) 0.0785
≥ 70 67/63 0.013 (0.021) (−0.028, 0.054) 0.5431
ALB-HFA albuterol hydrofluoroalkaline, CVT-MDI ipratropium bromide/albuterol sulfate metered-dose inhaler, FAS full analysis set, FEV1 forced expiratory volume in
1 s, FVC forced vital capacity, ICS inhaled corticosteroids, LABA long-acting β2-agonist, pre-BD at Rand pre-bronchodilator at randomization
aLast category not included in modelling due to insufficient number of patients
bAsian, Hawaiian/Pacific Islander and American Indian/Alaska National not included in modelling due to insufficient number of patients
*Unadjusted p values
Fig. 5 Forest plot of all subgroups for Peak FEV1
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significant improvement in efficacy over ALB-HFA for
FEV1 AUC0–6 response, and peak FEV1 response on day
29, indicating maintenance of effect without any evidence
of a loss of effect after 4 weeks of as-needed CVT-MDI use.
In a post-hoc analysis, the duration of bronchodilator re-
sponse at the end of the treatment period was twice as long
with CVT-MDI compared with ALB-HFA (137.5 min vs.
66.6 min, nominal p <0.0001); CVT-MDI has shown con-
sistent benefit in bronchodilation in all subgroups.
As anticipated for medications added for acute symptom
relief to maintenance therapy, overall asthma control did
not significantly differ between the CVT-MDI and ALB-
HFA groups in this short-term, crossover study. The ACQ
and mini-AQLQ were developed to measure effects of
long-term controller medications, while the investigational
medications used in this study were designed for acute
symptomatic relief during the 4-week active treatment
period. Despite significant differences in lung function, no
differences in rescue medication use were observed be-
tween the CVT-MDI and ALB-HFA groups. This suggests
that the weekly mean number of rescue puffs used per day
does not reflect potential differences in lung function im-
provement during acute symptom relief.
Increasing evidence shows the benefit of anticholinergic
agents in moderate-to-severe asthma, including recent
studies evaluating tiotropium as add-on therapy in uncon-
trolled asthma [28, 33–37]. In addition, a Cochrane review
of combined inhaled SAMAs and SABAs showed a lower
risk of hospital admission and a greater improvement
in lung function versus SABAs alone in acute asthma
in children [38].
Peters et al. showed that the addition of tiotropium to
low-dose ICS resulted in significant improvements in
morning and evening PEF, and pre-bronchodilator FEV1.
The combination of tiotropium and low-dose ICS was
comparable to a LABA/ICS combination and was signifi-
cantly better than doubling the ICS dose [28]. In a separ-
ate study of patients with severe uncontrolled asthma
despite treatment with at least high-dose ICS plus LABA,
the addition of tiotropium significantly improved lung
function; however, no significant differences were ob-
served in asthma-related health status or rescue medica-
tion use in this crossover and short-term setting, the
design of which may have impacted the clinical outcome
[33]. In a larger, 48-week study of a similar population of
patients, the add-on therapy of tiotropium to high-dose
ICS/LABA led to significant increases in lung function
and significantly increased the time to first severe asthma
exacerbation [34]. Bateman et al. showed that adding tio-
tropium to medium-dose ICS was non-inferior to salme-
terol and superior to placebo in patients with moderate
asthma with the B16-Arg/Arg genotype whose asthma
was not well controlled with ICS alone [35]. Once-daily
tiotropium Respimat® added on to ICS was shown to im-
prove lung function in symptomatic adult [36] and adoles-
cent [37] patients with moderate asthma. These studies
support a potentially important therapeutic role for the
long-acting anticholinergic tiotropium as maintenance
therapy in the treatment of patients with asthma.
In this study, the overall safety profile of CVT-MDI
was similar to ALB-HFA. As previously observed with
short-acting anticholinergics, patients receiving CVT-MDI
Table 5 Mean changes from study baseline for Mini-AQLQ, ACQ, and nighttime awakenings for the comparisons of CVT-MDI to
ALB-HFA, evaluated at 4 weeks
ALB-HFA CVT-MDI Difference (CVT-MDI – ALB-HFA)
Endpoint N Mean SE N Mean SE Mean (95 % CI) p value
Mini-AQLQ 191 0.15 0.05 193 0.22 0.05 0.06 (−0.03, 0.15) 0.159
ACQ 191 −0.25 0.04 193 −0.25 0.04 0.01 (−0.07, 0.08) 0.828
Nighttime awakenings 178 −0.15 0.02 180 −0.16 0.02 −0.01 (−0.05, 0.04) 0.764
ACQ asthma control questionnaire (7-point scale), ALB-HFA albuterol hydrofluoroalkaline, AQLQ asthma quality of life questionnaire, CVT-MDI ipratropium bromide/
albuterol sulfate metered-dose inhaler
Table 4 Analysis of number of puffs of study medication and open-label albuterol used during day and separately at night (mean
changes from study baselinea) at the end of the 4-week treatment period
ALB-HFA CVT-MDI Difference (CVT-MDI – ALB-HFA)
Endpoint n Mean SE N Mean SE Mean 95 % CI p value
Weekly meanb number of AM puffs of study medication used 176 −0.49 0.07 178 −0.53 0.07 −0.04 (−0.17, 0.08) 0.510
Weekly meanb number of PM puffs of study medication used 178 −0.10 0.05 180 −0.12 0.05 −0.02 (−0.12, 0.08) 0.659
Weekly meanb number of AM puffs of open label ALB-HFA used 176 −2.24 0.05 178 −2.28 0.05 −0.04 (−0.14, 0.05) 0.363
Weekly meanb number of PM puffs of open label ALB-HFA used 178 −0.92 0.02 180 −0.93 0.02 −0.01 (−0.06, 0.04) 0.679
SE standard error, 95 % CI 95 % confidence interval, ALB-HFA albuterol hydrofluoroalkaline, CVT-MDI ipratropium bromide/albuterol sulfate metered-dose inhaler
aMean observed in last week prior to administration of the first dose of the randomized treatment
bWeekly mean number of puffs during the fourth week of treatment
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Table 6 Characteristics of patients with severe asthma exacerbations
CVT-MDI ALB-HFA
Patient 10868 Patient 11356 Patient 11473 Patient 12410 Patient 12454 Patient 10853 Patient 11752 Patient 11803 Patient 12055
Age (years), gender,
race
52, Female,
Caucasian
69, Female,
Caucasian
64, Female,
Hawaiian/PI
36, Female,
Caucasian
59, Male,
Caucasian
45, Female,
Afr Amer
35, Male,
Afr Amer
49, Female,
Caucasian
74, Female,
Caucasian
BMI (kg/m2) 33.2 32.5 22.5 48.2 28.6 41.4 N/A N/A 29.0
Exacerbation - start day,
phase
Day 3, Ph 1 Day 2, Ph 1 Day 29, Ph 1 Day 24, Ph 1 Day 15, Ph 1 Day 19, Ph 2 Day 29, Ph 2 Day 11, Ph 2 Day 22, Ph 2
Exacerbation in prior year None Yes,
2 months
prior
None Yes, 6 months prior Yes, 2.5 months
prior
None N/A Yes, 6 months prior None
Baseline FEV1 % predicted 56.3 % 36.4 % 41.4 % 71.3 % 64.9 % 52.3 % 46.8 % 63.7 % 72.5 %
Background and concomitant
asthma medications (daily dose)
Advair 500/
100 μg; Alb
180 μg, d/c;
Symbicort
640/18 μg;
Advair 1000/
100 μg; Alb
180 μg, d/c;
Advair 250/50 μg;
Singulair 10 mg;
Zyrtec; Flonase;
Advair 1000/
100 μg;
Singulair 10 mg;
Advair 1000/
100 μg
Advair 1000/100 μg;
Singulair 10 mg;
Alb 180 μg, d/c;
Zyrtec D; Nasonex;
Flovent 440 μg,
Combivent 84/480 μg,
Alb 180 μg, d/c Flonase
Xopenex 2.5 mg,
Pulmicort 360 μg,
Alb, d/c
Respiratory infection reported
preceding exacerbation
No No No No No Yes Yes No No
Use of rescue medication
(No. of puffs) 3 days before
and day of exacerbation
−3 days: 2 −3 days: 2 −3 days: 4 −3 days: 0 −3 days: 5 −3 days: 2 −3 days: 6 −3 days: 6 −3 days: 4
−2 days: 4 −2 days: 3 −2 days: 8 −2 days: 2 −2 days: 4 −2 days: 0 −2 days: 8 −2 days:6 −2 days: 4
−1 day: 2 −1 day: 3 −1 day: 4 −1 day: 2 −1 day: 5 −1 day: 6 −1 day: 6 −1 day: 6 −1 day: 4
0: 4 0: 6 0: 0 0: 2 0: 7 0: 4 0: N/A 0: 6 0: 6
PEF (L/min) 3 days before
and day of exacerbation
(best of day)
−3 days: 365 −3 days: 189 −3 days: 155 −3 days: 381 −3 dy: 371 −3 days: 254 −3 days: 388 −3 days: 392 −3 days: 339
−2 days: 359 −2 days: 160 −2 days: 172 −2 dy: 392 −2 days: 399 −2 days: 227 −2 days: 298 −2 days: 395 −2 days: 334
−1 day: 353 −1 day: 180 −1 day: 129 −1 day: 426 −1 day: 337 −1 day: 180 −1 day: 307 −1 day: 406 −1 day: 305
0: 350 0: 181 0: 104 0: 368 0: 353 0: 194 0: 284 0: 374 0: 281
Duration of exacerbation 17 days 9 days 4 days 9 days 7 days 9 days 13 days 81 days 11 days
PEF (L/min) 3 days after end
of exacerbation
+1 day: 356 +1 day: 154 N/A +1 day: 368 +1 day: 492 +1 day: 310 N/A +1 day: 326 N/A
+2 days: 311 +2 days: 155 +2 days: 402 +2 days: 486 +2 days: 347 +2 days: 344
+3 days: 361 +3 days: 153 +3 days: 384 +3 days: 536 +3 days: 271 +3 days: 314
Afr Am African American, ALB-HFA albuterol hydrofluoroalkaline, Alb albuterol, BMI body mass index, CVT-MDI ipratropium bromide/albuterol sulfate metered-dose inhaler, d/c discontinued, FEV1 forced expiratory
volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroids, LABA long-acting β2-agonist, PEF peak expiratory flow, ph phase, PI pacific islander
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reported more cough. The patient population chosen for
this study had moderate-to-severe asthma, and was symp-
tomatic despite continuous treatment with ICS with or
without LABA and other asthma controller medications,
and had ACQ scores ≥1.5. Therefore, in this population
with poor asthma control, exacerbations are expected to
be more frequent. Although there was a slight excess of
patients in the CVT-MDI group (seven CVT-MDI vs. two
ALB-HFA patients) who met the protocol-defined criteria
for severe asthma exacerbation, no patients were hospital-
ized, and one patient discontinued on day 29 of the study
due to a severe asthma exacerbation. While differences in
the number of severe asthma exacerbations between the
groups were not significant, exacerbation data was exam-
ined in greater detail. An independent review of the severe
asthma exacerbations revealed no specific pattern except
that five of the seven patients who had severe asthma ex-
acerbations in the CVT-MDI group had a body mass
index (BMI) of 32.5–48.2 kg/m2. In two of these patients,
respiratory infection preceded the exacerbation.
Based on an analysis of the individual eDiary data,
there was no increased use or misuse of open label ALB-
HFA and/or blinded study medication before the onset
of the severe exacerbation in four of the seven CVT-
MDI group patients. There was also no evidence of a de-
crease in the PEF, indicating the onset of worsening of
asthma, in four of the seven CVT-MDI group patients.
Conclusions
These findings are consistent with those from recent
studies that demonstrated the value of using the long-
acting anticholinergic, tiotropium, as add-on therapy to
ICS [39], or as an add-on to ICS plus LABA [34, 40],
or compared with doubling the ICS dose [28], in the
chronic management of moderate or severe asthma. The
results of this study suggest that use of a short-acting anti-
cholinergic bronchodilator in a fixed-dose combination
with a SABA has a greater effect on lung function in
moderate-to-severe asthma than SABA alone, and should
therefore provide better symptomatic relief. In the future,
additional studies will be useful to investigate the additive
effects of these drugs in patients with all spectra of asthma
severity.
These results support the use of a short-acting anti-
cholinergic bronchodilator in a fixed-dose combination
with a SABA in asthma, and the need for further clinical
trials to determine the role of short- and long-acting an-
ticholinergics (ipratropium and tiotropium, respectively)
for managing asthma.
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